14 results about "Bephenium Compounds" patented technology

The present in vention is directed to methods of treating a metabolic disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a nitro-vinyl benzene compound and administering to the subject a therapeutically effective amount of a GLP-1 agonist or analog. The present invention is also directed to kits and / or pharmaceutical compositions suitable for practicing the claimed methods.

The application belongs to the technical field of aniline compound preparation, and particularly relates to a synthesis method of deuterated aniline based on transition metal catalyzed nitrobenzene compound. The method uses nitrobenzene compound as raw material, is catalyzed by a low-load transition metal catalyst, and adopts one-pot method to complete the series reaction of high-selectivity hydrogenation and hydrogen-deuterium exchange of the nitrobenzene compound, so that the deuterated aniline compound with high added value is obtained. The yield of the deuterated product and the deuterium substitution rate of the product are better than those of conventional hydrogenation and deuterium substitution, the product is stable and cannot be easily replaced by hydrogen to return to the raw material, and the operation and application are convenient.

The present invention addresses the problem of developing a rare-earth element separating agent having higher durability. The present invention provides: a compound in which diglycol amide acid is introduced into a supporting polymer via an alkyl-substituted benzene compound; and a rare-earth element separating agent and a rare-earth element recovering method which use said compound.

The present in vention is directed to methods of treating a metabolic disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a nitro-vinyl benzene compound and administering to the subject a therapeutically effective amount of a GLP-1 agonist or analog. The present invention is also directed to kits and / or pharmaceutical compositions suitable for practicing the claimed methods.

This invention relates to the field of nanomaterials, and discloses a composite nanoparticle, its preparation method, and its application. The preparation method includes: mixing noble metal nanoparticles with an organic synthetic oil and then heating the mixture to react; wherein the organic synthetic oil contains at least one selected from biphenyl compounds, hydrogenated products of biphenyl compounds, biphenyl ether compounds, and alkyl aromatic hydrocarbons. The composite nanoparticle includes a core and a shell covering the core; the core is a noble metal nanoparticle, and the shell is carbon quantum dots; wherein the carbon quantum dots are carbonized products of the organic synthetic oil; and the organic synthetic oil contains at least one selected from biphenyl compounds, hydrogenated products of biphenyl compounds, biphenyl ether compounds, and alkyl aromatic hydrocarbons. This composite nanomaterial exhibits excellent stability and light absorption properties.

The invention provides an ON-DNA 3, 4-substituted 3, 4-dihydroquinoxaline-2 (1H)-ketone compound and a preparation method thereof, and relates to the technical field of coding compound libraries. According to the invention, by controlling the conditions of solvent, temperature, pH and the like during reaction, the ON-DNA halogenated nitrobenzene compound can be used for preparing the ON-DNA 3, 4-substituted 3, 4-dihydroquinoxaline-2 (1H)-ketone compound through a two-step method. The method can be carried out in a mixed aqueous phase of an organic solvent / aqueous phase, has the advantages of single product, simple operation and environmental friendliness, and is suitable for synthesis of a DNA coding compound library by using a porous plate.

The present invention provides a novel EZH2 inhibitor compound represented by formula (I) and a use of the inhibitor compound in preventing or treating a disease mediated by EZH2.

Antibiotic resistance leads to deadly hospital-acquired infections globally. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have identified priority bacteria, including Methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, and particularly those carbapenem- resistant strains, also found in Enterobacterales (CRE) such as Escherichia coli and Klebsiella, as requiring new antibiotics. The present disclosure provides a chemical class of drugs less susceptible to existing mechanisms of antibiotic resistance and targeting difficult-to-treat bacterial infections. It more particularly provides compounds of formula (I), and compositions and uses thereof.

The application provides a production device, a production device control method and a preparation method of a phenyl chlorosilane. The production device comprises a reactor, a catalyst circulation device and a catalyst. The reactor is used for accommodating a reaction raw material and is provided with an outlet and an inlet. The catalyst circulation device is in communication with the outlet and the inlet respectively and is used for driving at least part of the catalyst to circulate in and out of the reactor. The reaction raw material comprises a chlorosilane and a benzene compound, and the catalyst comprises boron trifluoride or boron trichloride. The application can realize the recycling of the catalyst in the production process of the phenyl chlorosilane, separate the catalyst from hydrogen generated in the reaction, improve the reaction efficiency of the catalyst, and thus reduce the production cost of the phenyl chlorosilane.

The application belongs to the technical field of homogeneous catalysis, and provides application of a ten-core 3d-4f supramolecular nanocage material in catalyzing a three-component aza-Darzens reaction. The application comprises the following steps: mixing an aldehyde compound, an amino benzene compound, ethyl diazoacetate, the ten-core 3d-4f supramolecular nanocage material and an organic solvent, and then performing a reaction to obtain a reaction product, namely completing the three-component aza-Darzens reaction. The ten-core 3d-4f supramolecular nanocage material is used as a catalyst to catalyze the three-component aza-Darzens reaction to realize synthesis of a drug precursor with biological activity, and the catalyst has high catalytic efficiency, the operation steps are simple, and the yield of the target product is also high.

Provided are a novel method for producing a 3-hydroxybiphenyl compound, and a novel method for producing a derivative of a 3-hydroxybiphenyl compound using the same. Specifically, the present invention provides a method for producing a compound represented by formula (3), which comprises a step for reacting a compound represented by formula (1) (in the formula, R1, R2, R3, R4 and R5 are the same or different from each other and represent a hydrogen atom or the like, and R6 represents a phenylsulfonyl group or the like) with a compound represented by formula (2) (in the formula, a combination of R8 and R9 represents a combination of R8 being CH2NR12R13 or the like, R9 is a combination of hydrogen atoms or the like, R10 and R11 are the same or different from each other and represent a hydrogen atom or the like, and a combination of R8 and R9 is a combination of hydrogen atoms or the like). A compound represented by formula (1) (in the formula, R1, R2, R3, R4, R5, R10 and R11 represent the same meanings as the preamble) is obtained by reacting a compound represented by formula (2) in the presence of 0.1-5 moles of a base per 1 mole of the compound represented by formula (1) (in the formula, R1, R2, R3, R4, R5, R10 and R11 represent the same meanings as the preamble), and a compound represented by formula (3) (in the formula, R1, R2, R3, R4, R5, R10 and R11 represent the same meanings as the preamble).

The invention belongs to the field of biological medicine, and particularly relates to application of a biphenyl compound in resisting drug-resistant bacteria and a product. The invention provides an application of 2, 4-dihydroxy-4 '-pentylbiphenyl and / or 3, 5-dihydroxy-4'-pentylbiphenyl in preparation of a product for resisting drug-resistant bacteria, and a preparation method of the 2, 4-dihydroxy-4 '-pentylbiphenyl. The result of the embodiment shows that compared with other antibiotics such as penicillin, ceftaroline fosamil, oxacillin and levofloxacin, the 2, 4-dihydroxy-4 '-pentylbiphenyl and / or the 3, 5-dihydroxy-4'-pentylbiphenyl can effectively inhibit various drug-resistant bacteria, and the effect is good. The 3, 5-dihydroxy-4 '-pentylbiphenyl can damage cell nucleuses by destroying cell membranes so as to achieve an antibacterial effect, and has a remarkable inhibition effect on MRSA (Methicillin-Resistant Staphylococcus Aureus). The 2, 4-dihydroxy-4 '-pentylbiphenyl and the 3, 5-dihydroxy-4'-pentylbiphenyl disclosed by the invention are used for resisting drug-resistant bacteria, can effectively inhibit or kill various drug-resistant bacteria, and have a good effect.

The present invention is directed to methods of treating a metabolic disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a nitro-vinyl benzene compound and administering to the subject a therapeutically effective amount of a GLP-1 agonist or analog. The present invention is also directed to kits and / or pharmaceutical compositions suitable for practicing the claimed methods.

Disclosed in the present invention are a biphenyl compound, a method of preparation thereof, and an intermediate, a pharmaceutical composition and its uses. Specifically provided is a compound as shown in formula I or a pharmaceutically acceptable salt thereof. Said compound has good activity and selectivity at a γ retinoic acid receptor agonist, has virtually no agonistic activity at α and / or β retinoic acid receptors, and is thus beneficial for reducing systemic side effects.Preferably, the compound has a rather partial agonistic activity, has low skin irritation and few adverse reactions while maintaining its efficacy, and thus has good safety and compliance, such that the problems commonly present in existing RAR compounds are effectively resolved, and the compound can be used to treat and prevent diseases related to retinoic acid receptor γ.